Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Operating Expenses (2024 - 2025)

Maze Therapeutics has reported Operating Expenses over the past 2 years, most recently at $38.1 million for Q4 2025.

  • Quarterly Operating Expenses rose 28.03% to $38.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $142.9 million through Dec 2025, up 30.01% year-over-year, with the annual reading at $142.9 million for FY2025, 30.01% up from the prior year.
  • Operating Expenses was $38.1 million for Q4 2025 at Maze Therapeutics, up from $33.0 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $38.1 million in Q4 2025 and troughed at $25.4 million in Q2 2024.